ABBISKO-B (02256) announces a profit of no less than 10 million yuan for the year, turning losses into profits year on year.

ABBISKO-B (02256) announces that it is expected that the total revenue of the group for the year ending December 31, 2024 will be approximately RMB 504 million, an increase of approximately RMB 485 million compared to the total revenue of approximately RMB 190 million for the year ending December 31, 2023. The net profit for the year ending December 31, 2024 is expected to be no less than RMB 10 million, while the net loss for the year ending December 31, 2023 was approximately RMB 432 million. In addition to improving cost control through increasing operational efficiency, the growth in total revenue and return to profit are mainly attributed to the licensing agreement for pimicotinib (ABSK021) and the initial payment of $70 million (RMB 497 million) from Merck, which made a significant contribution to the revenue for the year ending December 31, 2024.